SOUTH SAN FRANCISCO, Calif., Sept. 20, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 3:35 p.m. ET in New York, NY.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Investors & Media Contacts:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$18.88 |
| Daily Change: | -0.72 -3.67 |
| Daily Volume: | 212,831 |
| Market Cap: | US$337.390M |
May 22, 2025 May 06, 2025 March 04, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
